Atara Biotherapeutics Inc at Citi BioPharma Conference (Virtual) Transcript
Okay. Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. Welcome to the panel on Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy. And it's my great pleasure to have with me today from Atara Bio, Pascal Touchon, who's the President and CEO; from Caribou Biosciences that recently went public, Rachel Haurwitz, President and CEO; from Cellectis, Andre Choulika, the CEO; and from Gracell Bio, William Cao, the Chairman and CEO. So welcome all of you today. Thank you very much for taking the time.
Questions & Answers
I think as a starting point for those less familiar with each of your companies, maybe we could just go through and do a brief introduction to the company and the pipeline and maybe comment as well on what you see as the strengths and differentiating qualities of your cell therapy platform. So maybe, Andre, you want to kick
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |